Zealand Pharma AS

22Z

Company Profile

  • Business description

    Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

  • Contact

    Sydmarken 11
    SoborgDK-2860
    DNK

    T: +45 88773600

    E: [email protected]

    https://www.zealandpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    578

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,600.19153.65-0.65%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,983.25678.77-1.14%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,596.645.93-0.16%

Market Movers